Background: Immune levels were observed by giving vitamin D supplements to vitamin D deficient women who received the COVID-19 vaccine. Methods: In the research, there were volunteer women who had received two doses of the COVID-19 vac-cine who participated for a mean of more than 65 days. Group D (n=14 Pfizer-BioNTech, 2 Sinovac) received 150,000 IU of vitamin D supplementation, but group C (n=14 Pfizer-BioNTech), 3 Sinovac) no support was provided. Results: When the consumption of vitamin D ends (D group), serum 25-Hydroxy Vitamin D levels were found to increase regularly in the (W3) last measurements (p=0.001). There was no significant difference in immunoglobulin M levels between groups D and C (Control group) (p=0.063). It was observed that the immunoglobulin G levels reached the peak level between the W1 and W2 measurements of the D group (P<0.001) and there were significant differences between the three sizes. Also, no correlation was found between the D group's initial serum immunoglobulin G and 25-Hydroxy Vitamin D levels. However, when the final measurements were examined, a significant positive correlation was found between immunoglobulin G and 25-Hydroxy Vitamin D levels (r=0.558, p=0.031). Conclusion: It was determined that serum IgG levels increased significantly depending on the duration between those who used vitamin D and those who did not and it was above the initial level for a long time. A positive and significant relationship was found between the last measured immunoglobulin G and 25(OH) D levels while vitamin D supplementation continued. Trial Registration: This study registered under ClinicalTrials.gov (Identifier no. NCT05447065)(c) 2023 Elsevier Ltd. All rights reserved.
Title (dc.title) | Impact of vitamin D3 supplementation on COVID-19 vaccine response and immunoglobulin G antibodies in deficient women: A randomized controlled trial |
Type (dc.type) | Makale |
Abstract (dc.description.abstract) | Background: Immune levels were observed by giving vitamin D supplements to vitamin D deficient women who received the COVID-19 vaccine. Methods: In the research, there were volunteer women who had received two doses of the COVID-19 vac-cine who participated for a mean of more than 65 days. Group D (n=14 Pfizer-BioNTech, 2 Sinovac) received 150,000 IU of vitamin D supplementation, but group C (n=14 Pfizer-BioNTech), 3 Sinovac) no support was provided. Results: When the consumption of vitamin D ends (D group), serum 25-Hydroxy Vitamin D levels were found to increase regularly in the (W3) last measurements (p=0.001). There was no significant difference in immunoglobulin M levels between groups D and C (Control group) (p=0.063). It was observed that the immunoglobulin G levels reached the peak level between the W1 and W2 measurements of the D group (P<0.001) and there were significant differences between the three sizes. Also, no correlation was found between the D group's initial serum immunoglobulin G and 25-Hydroxy Vitamin D levels. However, when the final measurements were examined, a significant positive correlation was found between immunoglobulin G and 25-Hydroxy Vitamin D levels (r=0.558, p=0.031). Conclusion: It was determined that serum IgG levels increased significantly depending on the duration between those who used vitamin D and those who did not and it was above the initial level for a long time. A positive and significant relationship was found between the last measured immunoglobulin G and 25(OH) D levels while vitamin D supplementation continued. Trial Registration: This study registered under ClinicalTrials.gov (Identifier no. NCT05447065)(c) 2023 Elsevier Ltd. All rights reserved. |
Author (dc.contributor.author) | FATİH CESUR |
Author (dc.contributor.author) | ZEYNEP ATASEVER |
Author (dc.contributor.author) | YAVUZ ÖZORAN |
Haklar (dc.rights) | Bronze, Green Published |
Publication Date (dc.date.issued) | 2023 |
Subject Headings (dc.subject) | POLYUNSATURATED FATTY-ACIDS |
Subject Headings (dc.subject) | IMMUNE-RESPONSE |
Subject Headings (dc.subject) | Immunology |
Subject Headings (dc.subject) | Medicine |
Subject Headings (dc.subject) | Research & Experimental |
Publisher (dc.publisher) | ELSEVIER SCI LTD |
Single Format Address (dc.identifier.uri) | https://hdl.handle.net/20.500.14429/4020 |
Açık Erişim Tarihi (dc.date.available) | 2023-11-16 |
ISSN (dc.identifier.issn) | 0264-410X |
Dergi Cilt (dc.identifier.volume) | 17 |
Dergi Sayısı (dc.identifier.issue) | 41 |
Yayının son sayfa sayısı (dc.identifier.endpage) | 2867 |
Yayının İlk Sayfa Sayısı (dc.identifier.startpage) | 2860 |
Editör/Editörler (dc.contributor.editor) | Fatih Cesur |
DOI Number (dc.identifier.doi) | http://dx.doi.org/10.1016/j.vaccine.2023.03.046 |
Dergi Adı (dc.relation.journal) | VACCINE |
Language (dc.language.iso) | ingilizce |
URL (dc.source.url) | https://www.sciencedirect.com/science/article/pii/S0264410X23003419?via%3Dihub |